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Abstract 
Bilateral macular hole is a rare secondary effect of tamoxifen, a condition which is probably 
underdiagnosed. We describe the case of a 63-year-old woman who had received low-dose 
treatment with tamoxifen for 10 years. She presented with a best-corrected visual acuity of 
20/40 in both eyes and bilateral macular hole with posterior hyaloid attachment. No reflective 
deposits were observed. A 23-gauge pars plana vitrectomy with internal limiting membrane 
peeling and gas tamponade was performed in the right eye with no anatomical or functional 
improvement. The most accepted mechanism of macular hole related to tamoxifen is Müller 
cell toxicity with retinal tissue loss. Therefore, it seems that the standard procedure used in 
idiopathic macular hole is not the optimal choice, due to a different pathogenic mechanism. 
 © 2020 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Tamoxifen is a non-steroidal selective estrogen receptor modulator used as adjuvant en-
docrine therapy in estrogen receptor-positive breast cancer. This drug can induce some ocular 
complications such as crystalline maculopathy, macular edema, retinal vein occlusions, 
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bilateral optic neuritis, and corneal opacities [1]. Recently, some studies have demonstrated 
that low-dose treatment can be extended up to 10 years, as tamoxifen can reduce relapse of 
cancer in patients at high risk of recurrence [2]. A relationship between the development of 
macular hole (MH) and low-dose tamoxifen (usually considered a cumulative dose <100 g) 
has been recently described [3–8], but the management remains controversial. 
Case Report 
A 63-year-old woman with a history of breast cancer presented with mild, progressive, 
bilateral visual loss for years with no prior ocular history. The patient had received 20 mg of 
tamoxifen daily for approximately 10 years (cumulative dose around 73 g). She began with 
this adjuvant therapy following a mastectomy, which had been done rapidly after diagnosis at 
age 41. Therefore, she had not received tamoxifen for 12 years at presentation. Her best cor-
rected visual acuity was 20/40 in both eyes (BE). Slit lamp examination of the anterior seg-
ment was unremarkable. Dilated fundus examination showed an irregular foveal light reflex 
with pseudohole appearance and no evidence of reflective deposits in the inner layers, which 
excluded crystalline maculopathy (Fig. 1a, b). Spectral-domain optical coherence tomography 
(SD-OCT) showed a bilateral MH with a thin overlying roof of inner retinal remnant. Some 
small cystic spaces on the edges of the hole and attachment of the posterior hyaloid (PH) were 
also observed with no evidence of thickening or macular edema (Fig. 1c, d). Fluorescein angi-
ography (FA) showed a progressive and diffuse hyperfluorescence in the fovea of BE with no 
late phase leakage (Fig. 2). FA allows to differentiate retinal changes related to tamoxifen ret-
inopathy, which may be similar on SD-OCT to the ones found in macular telangiectasia type 2 
(MacTel2) [9]. Nevertheless, a late leakage of telangiectatic macular capillaries is observed in 
FA of eyes with MacTel2 [10]. Thus, the diagnosis of bilateral MH related to tamoxifen toxicity 
was made. 
A 23-gauge pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling 
and sulfur hexafluoride (SF6) 24% gas tamponade was performed in the right eye (RE). The 
patient rested in prone position for 6 days. The MH remained opened with elevated edges 
after surgery (Fig. 3). A second 23-gauge PPV was proposed, but the patient rejected it. The 
patient has been followed for 4 years with no changes in visual acuity (best corrected visual 
acuity of 20/40 in BE) or SD-OCT images. 
Discussion 
The incidence of MH due to tamoxifen toxicity is expected to increase as the tendency is 
to extend low-dosage tamoxifen treatment. Furthermore, the increasing use of SD-OCT will 
probably raise the number of cases. Surgical outcome of secondary MH related to tamoxifen 
toxicity remains unclear. It is worth noticing that in our case BE showed still attached PH, 
which suggests a different pathomechanism from idiopathic MH, where anteroposterior and 
tangential traction forces after posterior vitreous detachment are thought to be the main 
cause of this condition. Therefore, it seems that in this type of secondary MH the standard 
procedure used in idiopathic MH (i.e., PPV with ILM peeling and gas tamponade) would not 
be effective, as it seems more related to degenerative mechanisms that lead to tissue loss in 
the retina. The most accepted mechanism of MH related to tamoxifen is that toxic damage 
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culminates in axonal degeneration leading to Müller cell impairment. It may cause intraretinal 
foveolar cysts, which in turn would predispose MH formation [11]. 
Due to the increasing use of SD-OCT and the new trend to extent low-dosage treatment, 
foveolar cavitations with outer retinal defect and MH related to tamoxifen have been de-
scribed [4, 5, 7, 8]. In 2005, Gualino et al. [3] first described this complication, and additionally 
in the same year, Cronin et al. [6] reported a retrospective analysis of 300 consecutive cases 
of MH and concluded that there was a statistically increased incidence of MH in women treated 
with tamoxifen.  
Concerning the crystalline deposits status in low-dose tamoxifen toxicity, crystalline ret-
inopathy has classically been thought to be the hallmark of tamoxifen toxicity. This association 
was based on patients treated with high-dose tamoxifen [12]. Superficial crystals have also 
been observed in patients with early cavitary spaces. Furthermore, more advanced cavitations 
without visible crystals have been demonstrated in patients who received low-dose tamoxifen 
[5, 7]. Thus, crystalline maculopathy could represent an earlier finding in tamoxifen toxicity 
with initial Müller cell damage, while foveal cavitations could correspond to a later stage of 
atrophy where the crystals have degenerated. Doshi et al. [7] also suggested this possibility 
after reporting the case of a woman who had received a cumulative dose of tamoxifen of 18.25 
mg with evidence of ILM draping with prominent crystals and a small cavitary space in the 
central fovea on the RE. On the contrary, the left eye of the same patient did not show any 
visible crystals, although a nearly full thickness cavitation was demonstrated [7]. Therefore, 
the absence of crystals in the posterior pole might be a common manifestation of late stages 
of low-dose tamoxifen maculopathy, although more longitudinal follow-up studies are needed 
to confirm this hypothesis. 
Regarding the treatment, Chung et al. [5] reported MH closure and visual improvement in 
two patients with MH related to systemic antiestrogen agents through surgery with solely 23-
gauge PPV and ILM peeling, although crystalline deposits were not found and there was no 
description about PH membrane status. Even though, Bernstein and DellaCroce [13] also pre-
sented the case of a woman who had received tamoxifen with bilateral MH coexisting with 
crystalline maculopathy who had a previous failed surgery on her RE elsewhere, which was 
not detailed. A new surgery on her RE with perfluoropropane (C3F8) tamponade successfully 
closed the MH. Nevertheless, the same surgery was performed on her left eye with no im-
provement and persistent MH on following examinations [13]. 
Conclusion 
We suggest that observation of MH related to low-dose tamoxifen is a feasible option at 
this time due to poor functional results after vitrectomy and ILM peeling found in our case and 
the previous case described by Bernstein and DellaCroce [13]. Nevertheless, more studies are 
needed in order to understand the evolution of tamoxifen associated with MH, possible pre-
cursor lesions, and their optimal management.  
Patients with reduced visual acuities may not be aware of their visual deficits initially, as 
in our case. Macular cavitations and holes due to tamoxifen may occur in the absence of sub-
jective visual complaints. Hence, we strongly recommend – whenever possible – a complete 
ophthalmologic exam including SD-OCT in those patients under treatment with tamoxifen, re-
gardless of subjective absence of visual impairment. 
Finally, if any macular cavitations are observed, a FA should be performed in order to 
exclude MacTel2. Thus, if any sign of retinal toxicity is detected promptly in those patients 
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under treatment with tamoxifen, progressive visual acuity deterioration could be avoided by 
considering tamoxifen discontinuation in agreement with the oncologist after considering the 
risk-benefit profile in each individualized case. 
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Fig. 1. a Fundus image of the right eye. b Fundus image of the left eye. An irregular foveal light reflex with 
a pseudohole appearance is shown in both eyes. c Optical coherence tomography of the right eye before 
surgery showing full thickness macular hole with some cystic spaces on the edges. The posterior hyaloid 
is attached and draping of the internal limiting membrane is also observed. d Optical coherence tomogra-
phy of the left eye showing a foveal cavitation with defect on the outer retinal layers and focal disruption 
of the photoreceptor layer with sharp edges, which present some cystic spaces. Internal limiting mem-




Fig. 2. Fluorescein angiography showing a progressive and diffuse hyperfluorescence in the fovea of both 
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Fig. 3. Optical coherence tomography of the right eye showing full thickness macula hole with thickened 
retinal edges 3 weeks after surgery. 
 
